Consistent with the clinical prognosis (Cui et al., 2015, 2016), hematopoietic-specific deletion of both Asxl1 and Tet2 leads to a much earlier onset of MDS than the deletion of Asxl1 or Tet2 alone. The gene discussed is TET2; the disease is myelodysplastic syndrome.